Jan 9 (Reuters) - Inovio Pharmaceuticals Inc:
* INOVIO PHARMACEUTICALS AND THE PARKER INSTITUTE FOR CANCER IMMUNOTHERAPY ESTABLISH CLINICAL DEVELOPMENT COLLABORATION TO EVALUATE NOVEL CANCER IMMUNOTHERAPY COMBINATIONS
* INOVIO PHARMACEUTICALS - UNDER AGREEMENT, PARKER INSTITUTE WILL HAVE RESPONSIBILITY FOR CLINICAL STUDY EXECUTION
* INOVIO PHARMACEUTICALS - WILL PROVIDE FINANCIAL CONTRIBUTIONS IF CO’S PRODUCT(S) STUDIED UNDER COLLABORATION REACHES INITIATION OF PHASE 3 STUDY Source text for Eikon: Further company coverage:
